Moderate aortic stenosis: culprit or bystander?
Varayini Pankayatselvan1, Inbar Raber2, David Playford3
1Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Insights
Untreated moderate aortic stenosis (AS) poses significant mortality risks. Emerging data suggests aortic valve replacement (AVR) may be beneficial, challenging traditional views on managing this common valvular disease.
Area of Science:
- Cardiology
- Valvular Heart Disease
- Cardiac Surgery
Background:
- Non-rheumatic aortic stenosis (AS) is a prevalent valvular heart disease in developed nations.
- Severe symptomatic AS guidelines recommend aortic valve replacement (AVR), but moderate AS management remains debated.
- Historically, moderate AS was considered benign, with AVR risks outweighing benefits.
Purpose of the Study:
- To review contemporary data on morbidity and mortality in moderate AS.
- To evaluate the evolving risk/benefit paradigm for AVR in moderate AS.
- To discuss current understanding, guidelines, and future directions for moderate AS management.
Main Methods:
- Literature review of current epidemiological data.
- Analysis of clinical outcomes and mortality risks associated with moderate AS.
- Appraisal of evolving guidelines and periprocedural/perioperative outcomes for AVR.
Main Results:
- Emerging data indicates substantial mortality risk in untreated moderate AS.
- Improvements in AVR periprocedural and perioperative mortality have been observed.
- Traditional risk/benefit assessments for moderate AS intervention are being challenged.
Conclusions:
- Contemporary data necessitates re-evaluation of moderate AS management strategies.
- The timing of AVR in moderate AS requires careful consideration based on updated evidence.
- Further studies are needed to refine surveillance and intervention thresholds for moderate AS.
Abstract:
Non-rheumatic aortic stenosis (AS) is among the most common valvular diseases in the developed world. Current guidelines support aortic valve replacement (AVR) for severe symptomatic AS, which carries high morbidity and mortality when left untreated. In contrast, moderate AS has historically been thought to be a benign diagnosis for which the potential benefits of AVR are outweighed by the procedural risks. However, emerging data demonstrating the substantial mortality risk in untreated moderate AS and substantial improvements in periprocedural and perioperative mortality with AVR have challenged the traditional risk/benefit paradigm. As such, an appraisal of the contemporary data on morbidity and mortality associated with moderate AS and appropriate timing of valvular intervention in AS is warranted. In this review, we discuss the current understanding of moderate AS, including the epidemiology, current surveillance and management guidelines, clinical outcomes, and future studies.
More Related Videos
Related Concept Videos
Mitral Stenosis I: Introduction
Aortic Regurgitation I: Introduction
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Aortic Regurgitation II: Clinical Features and Diagnostic Tests


